Aurobindo Pharma aims $2 billion turnover in FY15

05 Aug 2014 Evaluate

Leveraging on its large state-of-the-art manufacturing infrastructure for APIs and formulations, wide and diversified basket of products and confidence of its customers, Aurobindo Pharma is targeting to achieve $2 billion turnover during the current financial year. The city-based drug maker is also hoping to seek approvals for nine more injectables from US FDA.

The consolidated revenue (net) from operations was higher over the previous year by 38.3% at nearly Rs 8,100 crore ($1.4 billon at Rs 58 per dollar) during 2013-14 as against Rs 5,855 crore in the previous year.

The company has achieved a remarkable milestone of 300 submissions to the US FDA at the end of 2013 and as at end of March 2014 the submissions totaled 336 ANDA filings.

Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.

Aurobindo Pharma Share Price

1181.20 -6.00 (-0.51%)
31-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.75
Dr. Reddys Lab 1271.05
Cipla 1510.90
Zydus Lifesciences 914.65
Lupin 2112.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×